ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.
Rat and receptor-knockout mouse experiments found anti-allodynia effects that depended on the beta-common receptor, supporting a preclinical mechanism rather than human efficacy.
Rat and receptor-knockout mouse experiments found anti-allodynia effects that depended on the beta-common receptor, supporting a preclinical mechanism rather than human efficacy.
Research summary
ARA-290 reduced tactile and cold allodynia after experimental peripheral nerve injury in rats and wild-type mice. No effect was seen in beta-common receptor knockout mice. The authors proposed anti-inflammatory signaling as a contributor to the observed response.
Limitations and interpretation
Animal pain models do not establish clinical analgesic efficacy, safe human dosing, or an effective personal-use protocol. A functional knockout result does not by itself prove a specific physical receptor complex in humans.
Source
Swartjes M, Morariu A, Niesters M, et al. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice. Anesthesiology. 2011 Nov. DOI: 10.1097/ALN.0b013e31822fcefd. PMID: 21873879.
Original PubMed record. Publisher DOI. Sources reviewed October 15, 2026. This page is an educational summary, not a reproduction of the full publication.
Connected compound
ARA-290 / cibinetide monograph. Educational information only; no treatment or personal-use recommendations.
Keywords
Research Goals
(2)For research use only. Not medical advice.